Last C$4.28 CAD
Change Today +0.04 / 0.94%
Volume 2.6K
QLT On Other Exchanges
As of 1:00 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

qlt inc (QLT) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/14 - C$7.90
52 Week Low
12/16/14 - C$3.91
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for QLT INC (QLT)

qlt inc (QLT) Related Businessweek News

No Related Businessweek News Found

qlt inc (QLT) Details

QLT Inc., a biotechnology company, develops and commercializes ocular products that address the unmet medical needs of patients and clinicians worldwide. It focuses on the development of QLT091001, a synthetic retinoid compound, which is in phase Ib retreatment clinical trials for the treatment of leber congenital amaurosis and retinitis pigmentosa; phase Ib clinical trials for the treatment of Retinitis Pigmentosa with autosomal dominant mutation in RPE65; and phase IIa clinical trials for the treatment of impaired dark adaptation. The company was founded in 1981 and is headquartered in Vancouver, Canada.

37 Employees
Last Reported Date: 08/4/14
Founded in 1981

qlt inc (QLT) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: $233.8K
Compensation as of Fiscal Year 2013.

qlt inc (QLT) Key Developments

QLT Inc.(NasdaqGS:QLTI) added to NASDAQ Biotechnology Index

QLT Inc. will be added to the NASDAQ Biotechnology Index.

QLT Inc. Elects Six Directors

QLT Inc. announced at the AGM held on November 19, 2014, the shareholders elected Jason M. Aryeh, Dr. Geoffrey F. Cox PhD, Dr. John W. Kozarich PhD, Jeffrey A. Meckler, Dr. Stephen L. Sabba MD and John C. Thomas Jr. as directors.

QLT Mulls Strategic Options

QLT Inc. (TSX:QLT) continues its review of strategic and business options. QLT has engaged Greenhill & Co., Inc. (NYSE:GHL) to act as advisor to QLT in connection with developing, and advising QLT with respect to, various strategic and business alternatives for QLT. Strategic and business alternatives that QLT may consider include, but are not limited to, asset divestiture, partnering or other collaboration agreements, merger, reverse merger, reorganization or similar transactions, potential acquisitions, or recapitalizations, in addition to continuing to operate QLT in the ordinary course of business and developing its synthetic retinoid program.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QLT:CN C$4.28 CAD +0.04

QLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QLT.
View Industry Companies

Industry Analysis


Industry Average

Valuation QLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QLT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at